The serum estradiol/oocyte ratio in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins
ObjectiveTo investigate the patterns of estradiol-oocyte ratio (EOR) and estradiol-mature oocyte ratio (EMOR) in patients with breast cancer undergoing controlled ovarian stimulation (COS) using letrozole and gonadotropins for fertility preservation.MethodsThis retrospective study included 32 breast...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Society of Obstetrics and Gynecology
2018-03-01
|
Series: | Obstetrics & Gynecology Science |
Subjects: | |
Online Access: | http://ogscience.org/upload/pdf/ogs-61-242.pdf |
id |
doaj-b5c671907221476fbd07f8744edafbac |
---|---|
record_format |
Article |
spelling |
doaj-b5c671907221476fbd07f8744edafbac2020-11-25T03:53:15ZengKorean Society of Obstetrics and GynecologyObstetrics & Gynecology Science2287-85722287-85802018-03-0161224224610.5468/ogs.2018.61.2.242474The serum estradiol/oocyte ratio in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropinsYoo Jin Shim0Aeran Seol1Dayong Lee2Seul Ki Kim3Jung Ryeol Lee4Byung Chul Jee5Chang Suk Suh6Seok Hyun Kim7Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, .KoreaDepartment of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, .KoreaDepartment of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, .KoreaDepartment of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, .KoreaDepartment of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, .KoreaDepartment of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, .KoreaDepartment of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, .KoreaDepartment of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, .KoreaObjectiveTo investigate the patterns of estradiol-oocyte ratio (EOR) and estradiol-mature oocyte ratio (EMOR) in patients with breast cancer undergoing controlled ovarian stimulation (COS) using letrozole and gonadotropins for fertility preservation.MethodsThis retrospective study included 32 breast cancer patients underwent COS for fertility preservation and no patients had previously undergone gonadotoxic treatments. Basal characteristics and in vitro fertilization (IVF) outcomes were compared according to the age of women (age <35 vs. age ≥35) and the starting phase of ovarian stimulation (early follicular phase vs. late follicular phase vs. luteal phase).ResultsPatients who were administered with a letrozole-combined regimen, the peak serum estradiol (E2) was maintained at a low level (386.3±346.9 pg/mL). EOR was 52.4±78.8 pg/mL, and EMOR was 71.0±41.2 pg/mL. When the 2 groups were compared according to the age of women (age <35 vs. age ≥35), EOR was 34.5 (22.2–46.5) pg/mL and 40.7 (19.3–65.3) pg/mL, respectively; EMOR was 79.8 (40.8–90.6) pg/mL and 68.8 (44.5–85.9) pg/mL, respectively. There was no significant difference in the IVF outcomes. When the 2 groups were compared according to the starting phase of ovarian stimulation, there were no significant differences in IVF outcomes, EOR and EMOR among the groups.ConclusionMeasuring the peak E2 concentration in breast cancer patients undergoing IVF for fertility preservation with a co-treatment of letrozole allows for the prediction of the numbers of oocytes and mature oocytes.http://ogscience.org/upload/pdf/ogs-61-242.pdfbreast neoplasmsfertility preservationaromatase inhibitorsestradiol fertilization |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yoo Jin Shim Aeran Seol Dayong Lee Seul Ki Kim Jung Ryeol Lee Byung Chul Jee Chang Suk Suh Seok Hyun Kim |
spellingShingle |
Yoo Jin Shim Aeran Seol Dayong Lee Seul Ki Kim Jung Ryeol Lee Byung Chul Jee Chang Suk Suh Seok Hyun Kim The serum estradiol/oocyte ratio in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins Obstetrics & Gynecology Science breast neoplasms fertility preservation aromatase inhibitors estradiol fertilization |
author_facet |
Yoo Jin Shim Aeran Seol Dayong Lee Seul Ki Kim Jung Ryeol Lee Byung Chul Jee Chang Suk Suh Seok Hyun Kim |
author_sort |
Yoo Jin Shim |
title |
The serum estradiol/oocyte ratio in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins |
title_short |
The serum estradiol/oocyte ratio in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins |
title_full |
The serum estradiol/oocyte ratio in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins |
title_fullStr |
The serum estradiol/oocyte ratio in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins |
title_full_unstemmed |
The serum estradiol/oocyte ratio in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins |
title_sort |
serum estradiol/oocyte ratio in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins |
publisher |
Korean Society of Obstetrics and Gynecology |
series |
Obstetrics & Gynecology Science |
issn |
2287-8572 2287-8580 |
publishDate |
2018-03-01 |
description |
ObjectiveTo investigate the patterns of estradiol-oocyte ratio (EOR) and estradiol-mature oocyte ratio (EMOR) in patients with breast cancer undergoing controlled ovarian stimulation (COS) using letrozole and gonadotropins for fertility preservation.MethodsThis retrospective study included 32 breast cancer patients underwent COS for fertility preservation and no patients had previously undergone gonadotoxic treatments. Basal characteristics and in vitro fertilization (IVF) outcomes were compared according to the age of women (age <35 vs. age ≥35) and the starting phase of ovarian stimulation (early follicular phase vs. late follicular phase vs. luteal phase).ResultsPatients who were administered with a letrozole-combined regimen, the peak serum estradiol (E2) was maintained at a low level (386.3±346.9 pg/mL). EOR was 52.4±78.8 pg/mL, and EMOR was 71.0±41.2 pg/mL. When the 2 groups were compared according to the age of women (age <35 vs. age ≥35), EOR was 34.5 (22.2–46.5) pg/mL and 40.7 (19.3–65.3) pg/mL, respectively; EMOR was 79.8 (40.8–90.6) pg/mL and 68.8 (44.5–85.9) pg/mL, respectively. There was no significant difference in the IVF outcomes. When the 2 groups were compared according to the starting phase of ovarian stimulation, there were no significant differences in IVF outcomes, EOR and EMOR among the groups.ConclusionMeasuring the peak E2 concentration in breast cancer patients undergoing IVF for fertility preservation with a co-treatment of letrozole allows for the prediction of the numbers of oocytes and mature oocytes. |
topic |
breast neoplasms fertility preservation aromatase inhibitors estradiol fertilization |
url |
http://ogscience.org/upload/pdf/ogs-61-242.pdf |
work_keys_str_mv |
AT yoojinshim theserumestradioloocyteratioinpatientswithbreastcancerundergoingovarianstimulationwithletrozoleandgonadotropins AT aeranseol theserumestradioloocyteratioinpatientswithbreastcancerundergoingovarianstimulationwithletrozoleandgonadotropins AT dayonglee theserumestradioloocyteratioinpatientswithbreastcancerundergoingovarianstimulationwithletrozoleandgonadotropins AT seulkikim theserumestradioloocyteratioinpatientswithbreastcancerundergoingovarianstimulationwithletrozoleandgonadotropins AT jungryeollee theserumestradioloocyteratioinpatientswithbreastcancerundergoingovarianstimulationwithletrozoleandgonadotropins AT byungchuljee theserumestradioloocyteratioinpatientswithbreastcancerundergoingovarianstimulationwithletrozoleandgonadotropins AT changsuksuh theserumestradioloocyteratioinpatientswithbreastcancerundergoingovarianstimulationwithletrozoleandgonadotropins AT seokhyunkim theserumestradioloocyteratioinpatientswithbreastcancerundergoingovarianstimulationwithletrozoleandgonadotropins AT yoojinshim serumestradioloocyteratioinpatientswithbreastcancerundergoingovarianstimulationwithletrozoleandgonadotropins AT aeranseol serumestradioloocyteratioinpatientswithbreastcancerundergoingovarianstimulationwithletrozoleandgonadotropins AT dayonglee serumestradioloocyteratioinpatientswithbreastcancerundergoingovarianstimulationwithletrozoleandgonadotropins AT seulkikim serumestradioloocyteratioinpatientswithbreastcancerundergoingovarianstimulationwithletrozoleandgonadotropins AT jungryeollee serumestradioloocyteratioinpatientswithbreastcancerundergoingovarianstimulationwithletrozoleandgonadotropins AT byungchuljee serumestradioloocyteratioinpatientswithbreastcancerundergoingovarianstimulationwithletrozoleandgonadotropins AT changsuksuh serumestradioloocyteratioinpatientswithbreastcancerundergoingovarianstimulationwithletrozoleandgonadotropins AT seokhyunkim serumestradioloocyteratioinpatientswithbreastcancerundergoingovarianstimulationwithletrozoleandgonadotropins |
_version_ |
1724479194147061760 |